Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor

NCT02639910 is registered in ClinicalTrials.gov with MorphoSys AG as lead sponsor.

NCT NCT02639910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02639910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor
Lead sponsor
MorphoSys AG
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2016
Completion date
December 31, 2021
Enrollment
24 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, leukemia, lymphocytic, chronic, b-cell, small lymphocytic lymphoma